Shots:

• This is the first launch of a biosimilar to Humira in Japan. Mylan EPD will lead the commercialization of the biosimilar
• The launch is a testament to the power of Viatris' unique Global Healthcare Gateway which helps partners to further expand patient access to more affordable medicines across the globe
• In 2018- Fujifilm Kyowa Kirin Biologics and Viatris collaborated for the commercialization of Hulio in the EU and Viatris has commercialized the product in 20+ countries across the region. In 2019- the companies expanded the partnership globally

 ­ Ref: Biosimilar Development | Image: PRNewswire